LGM
NGNE icon

Logos Global Management’s Neurogene NGNE Stock Holding History

Logos Global Management’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-195,000
Closed -$4.02M – 78
2025
Q4 		$4.02M Buy
+195,000
New +$4.85M 0.24% 55
2020
Q1 		– Sell
-2,026
Closed -$499K – 51
2019
Q4 		$499K Buy
+2,026
New +$202K 0.12% 39

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Logos Global Management's NGNE Position: Q1 2026 in Review

Logos Global Management sold out of Neurogene (NGNE) in Q1 2026, closing a stake of 195,000 shares — an estimated $4.02M sold.

Logos Global Management first reported a position in NGNE in Q4 2019 and held it in 2 quarters. The position peaked at $4.02M in Q4 2025. 96 funds tracked by Wall St. Rank hold NGNE as of Q1 2026.

  • Logos Global Management reported no remaining Neurogene position as of Q1 2026 after selling out during the quarter.
  • Logos Global Management sold 195,000 Neurogene shares in Q1 2026, an estimated $4.02M.
  • Logos Global Management first reported a position in Neurogene in Q4 2019 and held it in 2 quarters.
  • Logos Global Management's Neurogene position peaked at $4.02M in Q4 2025.
  • 96 funds tracked by Wall St. Rank held Neurogene as of Q1 2026.

Based on Logos Global Management's 13F filing for Q1 2026, filed 15 May 2026.